The global Acetazolamide Market is estimated to be valued at US$ 183.2 million in 2017 and is expected to exhibit a CAGR of 4.8% over the forecast period from 2018 to 2026, according to a new report published by Coherent Market Insights.
A) Market Overview:
Acetazolamide is a carbonic anhydrase inhibitor that is primarily used to treat glaucoma and altitude sickness. It helps to reduce the production of aqueous humor in the eyes, thereby lowering intraocular pressure and ... Read more
Glaucoma is a leading cause of blindness worldwide, affecting over 60 million people. Traditional drug therapies for glaucoma such as prostaglandin analogues, beta blockers, and alpha agonists have been mainstays of treatment for decades. However, researchers continue working to develop new drugs with improved safety and tolerability profiles. A growing number of fixed-dose combination medications now allow for simultaneous treatment of multiple ... Read more
